Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 12 Nov 2012 Primary endpoint 'Apnea-hypopnea-index' has been met.
- 17 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2010 New trial record